The Expression of Immune Checkpoint Inhibitors PDL-1 and CTLA-4 in Pancreatic Versus Non-Pancreatic Periampullary Adenocarcinoma: An Immunohistochemical Study

Assessment of PD-L1 and p53 expression in urinary bladder carcinoma: Association with different clinicopathologic characteristics

Immunohistochemical expression of programmed death-ligand 1 (PD-L1) in invasive duct carcinoma of the breast of no special type and correlation with patients' clinicopathological

Evaluation of Histopathological and Prognostic Significance of Programmed Death Ligand 1 (PD-L1) Expression of Cutaneous Squamous Cell Carcinoma and Basal Cell Carcinoma

PD-L1 Expression in Colorectal Cancer and Its Relation to Microsatellite Instability and Cytotoxic Tumor-Infiltrating Lymphocytes

PD-L1 Expression in Colorectal Cancer and Its Relation to Microsatellite Instability and Cytotoxic Tumor-Infiltrating Lymphocytes

High expression of the checkpoint molecule PD-1 on conventional CD4+ and regulatory T cells in the peripheral blood of Hepatocellular carcinoma patients

Assessment of PI3KCA immunohistochemical expression and tumor infiltrating lymphocytes (CD4 and CD8) in invasive breast carcinoma and their relation to molecular subtypes

CLINICOPATHOLOGICAL SIGNIFICANCE OF PROGRAMED DEATH -LIGAND -1(PD-L1) AND PROLIFERATION CELL NUCLEAR ANTIGE(PCNA)EXPRESSION IN PROSTATIC CARCINOMA; AN IMMUNOHISTOCHEMICAL STUDY"

Prognostic Value of Programed Cell Death-1 Ligand Expression in Colorectal Cancer and Its Correlation with Cytotoxic Tumor-Infiltrating Lymphocytes